PCVX in the 13F filings
Vaxcyte Inc · CUSIP 92243G108
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 28
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 8 listed it in both
- Shares listed
- 42,644,753
- combined, among listed positions
- Reported value
- $2.0bn
- combined, at the quarter end
Among the 92 comparable managers: 13 buyers (opened or added shares) and 18 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -527,155.
Managers listing PCVX in Q4 2025
28 of 28 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 13,834,514 shares now+1,324,581
- Wellington Management Group LLPexisting position · 5,966,310 shares now+933,539
- Artisan Partners LPnew position · 304,049 shares now+304,049
- Janus Henderson Group Ltdexisting position · 13,387,188 shares now+282,985
- Citadel Advisors LLCexisting position · 326,574 shares now+120,775
Reductions
- D. E. Shaw & Co.existing position · 3,631,053 shares now-659,737
- Point72 Asset Management LPexisting position · 161,614 shares now-535,229
- Millennium Management LLCexisting position · 424,294 shares now-524,673
- T. Rowe Price Associates Incexisting position · 1,175,339 shares now-513,144
- Balyasny Asset Management LLCexisting position · 26,865 shares now-251,268
New positions and exits
New (6)
Exited (4)
- Voloridge Investment Management LLCwas $19m
- Tudor Investment Corpwas $2.6m
- Schonfeld Strategic Advisors LLCwas $1.0m
- Bridgewater Associates LPwas $427k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2020 | 2 | $141m | n.a. | n.a. |
| Q3 2020 | 2 | $515m | n.a. | n.a. |
| Q4 2020 | 1 | $108m | n.a. | n.a. |
| Q1 2021 | 1 | $84m | n.a. | n.a. |
| Q2 2021 | 1 | $93m | n.a. | n.a. |
| Q3 2021 | 1 | $104m | n.a. | n.a. |
| Q4 2021 | 2 | $103m | n.a. | n.a. |
| Q1 2022 | 2 | $106m | n.a. | n.a. |
| Q2 2022 | 4 | $107m | n.a. | n.a. |
| Q3 2022 | 5 | $140m | n.a. | n.a. |
| Q4 2022 | 12 | $1.2bn | n.a. | n.a. |
| Q1 2023 | 8 | $978m | n.a. | n.a. |
| Q2 2023 | 8 | $1.6bn | n.a. | n.a. |
| Q3 2023 | 9 | $1.8bn | n.a. | n.a. |
| Q4 2023 | 9 | $2.1bn | 5 | 4 |
| Q1 2024 | 9 | $2.7bn | 8 | 1 |
| Q2 2024 | 10 | $3.1bn | 4 | 6 |
| Q3 2024 | 12 | $5.1bn | 8 | 4 |
| Q4 2024 | 11 | $3.6bn | 6 | 6 |
| Q1 2025 | 6 | $1.8bn | 3 | 3 |
| Q2 2025 | 7 | $969m | 5 | 2 |
| Q3 2025 | 9 | $940m | 5 | 5 |
| Q4 2025 | 9 | $1.8bn | 13 | 18 |
| Q1 2026 | 12 | $2.7bn | 18 | 13 |
| Q2 2026 | 8 | $2.9bn | 13 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
PCVX and GILD →PCVX and AMGN →PCVX and ARGX →Choose a stock to compare with PCVX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own PCVX, latest filings →Back to the 13F Explorer →